Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
18.81
-1.73 (-8.42%)
At close: Mar 6, 2026, 4:00 PM EST
18.00
-0.81 (-4.31%)
After-hours: Mar 6, 2026, 4:55 PM EST
Aktis Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 5.56 | 1.49 | - | - |
| Cost of Revenue | 63.56 | 40.95 | 25.92 | - |
| Gross Profit | -58 | -39.47 | -25.92 | - |
| Selling, General & Admin | 14.94 | 12.58 | 8.88 | 5.46 |
| Research & Development | - | - | - | 14.3 |
| Operating Expenses | 14.94 | 12.58 | 8.88 | 19.76 |
| Operating Income | -72.94 | -52.05 | -34.79 | -19.76 |
| Interest & Investment Income | 12.34 | 8.1 | 5.38 | 1.65 |
| Other Non Operating Income (Expenses) | -0.05 | -0.03 | 0.78 | 0.19 |
| Pretax Income | -60.65 | -43.98 | -28.64 | -17.93 |
| Net Income | -60.65 | -43.98 | -28.64 | -17.93 |
| Net Income to Common | -60.65 | -43.98 | -28.64 | -17.93 |
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 |
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 |
| Shares Change (YoY) | 53.35% | 14.46% | 18.90% | - |
| EPS (Basic) | -76.44 | -62.46 | -46.55 | -34.65 |
| EPS (Diluted) | -76.44 | -62.46 | -46.55 | -34.65 |
| Free Cash Flow | -69.34 | 11.9 | -33.77 | -20.43 |
| Free Cash Flow Per Share | -87.40 | 16.90 | -54.89 | -39.49 |
| Operating Margin | -1311.94% | -3500.34% | - | - |
| Profit Margin | -1090.81% | -2957.63% | - | - |
| Free Cash Flow Margin | -1247.19% | 800.27% | - | - |
| EBITDA | -70.87 | -50.48 | -33.67 | -19.32 |
| D&A For EBITDA | 2.08 | 1.58 | 1.12 | 0.45 |
| EBIT | -72.94 | -52.05 | -34.79 | -19.76 |
Source: S&P Capital IQ. Standard template.
Financial Sources.